50 Participants Needed

Lenacapavir for HIV

CW
KR
CC
Overseen ByChuen-Yen C Lau, M.D.
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Must be taking: ART
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial requires you to stop taking certain medications, including specific antiarrhythmics, anticoagulants, anticonvulsants, antiretroviral agents, antimycobacterials, systemic corticosteroids, ergot derivatives, herbal products like St. John's wort, certain cholesterol medications, some narcotic analgesics, opioid dependence treatments, opioid antagonists, PDE-5 inhibitors, and certain sedatives. If you are on any of these, you may need to stop them to participate in the trial.

What data supports the effectiveness of the drug Lenacapavir for HIV treatment?

Lenacapavir has been shown to be effective in treating HIV, especially in people with multidrug-resistant HIV who have limited treatment options. Clinical trials demonstrated its ability to work well when combined with other HIV medications, and it was approved by the U.S. Food and Drug Administration for this purpose.12345

Is Lenacapavir safe for humans?

Lenacapavir has been tested in clinical trials for people with multidrug-resistant HIV and was generally well tolerated. The most common side effects were mild to moderate reactions at the injection site, stomach issues, and headaches.15678

What makes the drug Lenacapavir unique for treating HIV?

Lenacapavir is unique because it is a first-in-class capsid inhibitor, which means it targets a different part of the HIV virus than other drugs. It can be given as an injection every six months, reducing the need for daily pills, which is especially helpful for people with multidrug-resistant HIV.14689

What is the purpose of this trial?

Pending...

Research Team

CC

Chuen-Yen C Lau, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility Criteria

This trial is for adults aged 18-75 with HIV who are in good health, have been on antiretroviral therapy (ART) for over 3 years with a suppressed viral load, and have a CD4+ T cell count above 200. They must not be pregnant or breastfeeding and agree to use contraception. Exclusions include recent illness, drug abuse, certain medication use, other infections like hepatitis B/C, and inability to undergo leukapheresis.

Inclusion Criteria

Able to provide informed consent
In generally good health with an identified primary health care provider for medical management of HIV infection and willing to maintain a relationship with a primary health care provider while participating in the study
Confirmed HIV-1 infection
See 6 more

Exclusion Criteria

Laboratory abnormalities in specified parameters
I have not had an AIDS-defining illness in the last 3 years.
Pregnancy or lactation
See 11 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive lenacapavir intensification or continue ART alone

48 weeks
Injections at weeks 0, 24, and 48; oral doses on days 0 and 1

Follow-up

Participants are monitored for safety and effectiveness after treatment

48 weeks
Visits at weeks 12, 24, 48, 72, and 96

Treatment Details

Interventions

  • Lenacapavir
Trial Overview The trial is testing Lenacapavir's ability to disrupt HIV reservoirs in people whose virus is already under control with ART. Participants will receive Lenacapavir intensification alongside their current treatment regimen to assess its impact on the size of the HIV reservoir.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionalExperimental Treatment1 Intervention
Participants will receive lenacapavir at 927 mg by subcutaneous injection (2x1.5 mL injections) on day 0 and 600 mg orally (2x300 mg tablets) on days 0 and 1, followed by 927 mg by subcutaneous injection (2x1.5 mL injections) at weeks 24 and 48.
Group II: Standard of CareActive Control1 Intervention
Participants who are not randomized to lenacapavir will remain on their current ART regimens.

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials
3,361
Recruited
5,516,000+

Findings from Research

Lenacapavir (LEN) is a novel capsid inhibitor that offers a unique treatment option for heavily treatment-experienced (HTE) HIV-1 patients, demonstrating efficacy in achieving viral suppression and immune restoration when combined with other antiretrovirals.
Administered subcutaneously twice a year, lenacapavir provides a convenient dosing schedule, making it a well-tolerated and effective addition to existing HIV treatment regimens.
Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.Tailor, MW., Chahine, EB., Koren, D., et al.[2023]
Lenacapavir is the first FDA-approved capsid inhibitor for treating multidrug-resistant HIV-1, specifically for heavily treatment-experienced adults whose current therapies are failing due to resistance or safety issues.
In a phase 3 clinical trial, lenacapavir significantly reduced viral load compared to placebo, and it is administered as a long-acting injection every 6 months, although 63% of participants experienced injection site reactions.
Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.Prather, C., Lee, A., Yen, C.[2023]

References

Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. [2023]
Lenacapavir: a first-in-class HIV-1 capsid inhibitor. [2023]
Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus. [2023]
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. [2023]
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. [2023]
Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. [2023]
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. [2023]
Lenacapavir: A novel injectable HIV-1 capsid inhibitor. [2023]
Antiviral Activity of Lenacapavir Against HIV-2 Isolates and Drug-resistant HIV-2 Mutants. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security